Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 70/100

Failure Rate

33.3%

1 terminated/withdrawn out of 3 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

33%

1 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
2(66.7%)
Phase 4
1(33.3%)
3Total
N/A(2)
Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT02464501Not ApplicableCompleted

The OPC for Optimal Delivery of Paclitaxel for the Prevention of Endovascular Restenosis - Above and Below the Knee

Role: lead

NCT02395744Not ApplicableCompleted

The COPPER-B Trial

Role: lead

NCT02156336Phase 4Terminated

Ranolazine for Diabetic Peripheral Neuropathic Pain (DPNP)

Role: lead

All 3 trials loaded